Moran Brendan J, Cecil Thomas D
Pseudomyxoma Peritonei Centre, North Hampshire Hospital, Aldermaston Road, Basingstoke, Hampshire, RG24 9NA, United Kingdom.
Surg Oncol Clin N Am. 2003 Jul;12(3):585-603. doi: 10.1016/s1055-3207(03)00026-7.
PMP is a rare condition, which, although of "borderline malignancy," is invariably fatal. Difficulties exist with the definition of PMP. It has been broadly applied to include a heterogenous group of pathologic lesions that present clinically with "jelly belly" due to mucinous ascites. The relatively few reports in the literature commonly use different pathologic definitions, and there is no consensus on the point of separation between PMP and carcinomatosis secondary to a mucinous adenocarcinoma. Sugarbaker has suggested "the term pseudomyxoma peritonei syndrome be strictly applied to a pathologically and prognostically homogenous group of cases characterized by histologically benign peritoneal tumors that are frequently associated with an appendiceal mucinous adenoma." This definition excludes all cases with mucinous adenocarcinoma. The optimal treatment is undoubtedly complete tumor excision, by complex surgical peritonectomy procedures, taking on average 10 hours. Surgery is usually combined with intraperitoneal, and now intraoperative heated chemotherapy. These techniques have a high morbidity and mortality. The rarity of the condition, together with the risks associated with definitive treatment, suggests that such treatment ought to be centralized in a few centers, covering a large population. The search continues for safer, less aggressive treatments, but is hampered by a lack of hard evidence and the absence of experimental animal or human models to evaluate emerging strategies.
腹膜假黏液瘤(PMP)是一种罕见疾病,尽管属于“交界性恶性”,但无一例外都是致命的。PMP的定义存在困难。它被广泛应用于包括一组异质性病理病变,这些病变临床上因黏液性腹水而表现为“果冻腹”。文献中相对较少的报告通常使用不同的病理定义,并且对于PMP与黏液性腺癌继发的癌性腹膜炎之间的区分点尚无共识。苏格贝克建议“腹膜假黏液瘤综合征这一术语应严格应用于一组病理和预后均一的病例,其特征为组织学上良性的腹膜肿瘤,常与阑尾黏液性腺瘤相关”。该定义排除了所有黏液性腺癌病例。最佳治疗方法无疑是通过复杂的手术腹膜切除术完全切除肿瘤,平均需要10个小时。手术通常联合腹腔内,现在还有术中热化疗。这些技术有较高的发病率和死亡率。该疾病的罕见性,以及确定性治疗相关的风险,表明这种治疗应该集中在少数几个覆盖大量人群的中心进行。人们一直在寻找更安全、侵袭性更小的治疗方法,但由于缺乏确凿证据以及缺乏评估新出现策略的实验动物或人体模型而受到阻碍。